Alivus Life Sciences Ltd

Stage 2 · Advancing · week 27Setup 5.3 ★ FairSolid +5.6

As of 16 Oct 2026, Alivus Life Sciences is in Stage 2 — advancing, the uptrend phase, in week 27 (since 10 Apr 2026). It closed at ₹1,310, 9.3% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. More about the company

₹1,309.5
-2.41% today
₹16,077 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.3 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #18 of 59 in Pharmaceuticals · #22 of 70 in Health Care

Is ALIVUS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-9.3%
₹860.1 lo₹1,443.7 hi
9.3% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 27
1w13w26w
Week 27 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
18.6%
200 DMA: ₹1,104.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.24x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -1.3% vs MA50 +6.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.5%
3M
+15.5%
6M
+22.2%
YTD
+43.5%
1Y
+42.4%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #20 of 66 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #17 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2025-01-13 → 2026-10-16
S? 42w
S4 16w
S1 7w
S2 27w
2025-01-132026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 16w → S1 7w → S2 27w current
Total tracked: 92 weeks across 4 stage runs.
Scan Membership
Prop Scan
Latest: 2026-08-03
Pullback Hunter
Latest: 2026-07-30
60 appearances in last 60 days. First seen: 2026-05-14.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 27 · Vol 0.24x
2026-10-15S2
Wk 27 · Vol 0.30x
2026-10-14S2
Wk 27 · Vol 0.46x
2026-10-13S2
Wk 26 · Vol 0.43x
2026-10-12S2
Wk 26 · Vol 0.25x
2026-10-09S2
Wk 26 · Vol 0.75x
2026-10-08S2
Wk 26 · Vol 0.47x
2026-10-07S2
Wk 26 · Vol 0.45x
2026-10-06S2
Wk 25 · Vol 0.97x
2026-10-05S2
Wk 25 · Vol 0.57x
2026-10-01S2
Wk 25 · Vol 0.66x
2026-09-30S2
Wk 25 · Vol 1.12x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,371.4
200 DMA
₹1,104.6
52W High
₹1,443.7
52W Low
₹860.1
5D Low
₹1,309.5
Resistance levels (recent highs)
20d High
₹1,430.8
60d High
₹1,443.7
120d High
₹1,443.7
250d High
₹1,443.7
Next resistance
+9.3%
to 20d High
Ask the Market AI about ALIVUSAsk →
P/E (TTM)
23.3
Forward 18.6
Earnings Growth (YoY)
+14.5%
Revenue +6.1%
ROE
+18.4%
Profit margin +22.1%
Dividend Yield
0.46%
P/B 3.9
About this companyHealth Care· Pharmaceuticals

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.